Clinical Trial Update: "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial updates for baricitinib in hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospital-acquired Pneumonia

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Nantes University Hospital | Conditions: Hospital-acquired Pneumonia | Phase 2, Phase 3 | Status: UNKNOWN